Practical management of patients on Janus kinase inhibitor (JAKi) therapy - the CRI fact sheets - 30/10/19
DISCLOSURE OF INTEREST Christophe RICHEZ: grant from Lilly to the Club Rhumatismes et Inflammation (CRI) in financial support to help with writing, no personal fees from Lilly for participation as the convenor of this initiative. Personal fees from Pfizer, Lilly, Roche, Abbvie, Amgen, Mylan, UCB, outside the submitted work. Jacques MOREL: grants and personal fees from Pfizer, personal fees from Lilly, Medac, all outside the submitted work. Jean SIBILIA has no conflicts of interest to report. Thao PHAM: personal fees from Abbvie, Biogen, Fresenius-Kabi, Gilead, Janssen, Lilly, MSD, Nordic, Novartis, Pfizer, Sandoz, Sanofi, UCB; grants from BMS, all outside the submitted work. |
Vol 86 - N° S1
P. eS1 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?